Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

BioMarin

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of BioMarin's 2012 metabolic sales performance.

Pharma deals during September 2013

Pharma deals during September 2013 Alexion, Biomarin and ViroPharma have all been under the spotlight this month as speculation shifts from large Pharma looking to get in on the action or an existing niche player making

AZ moves closer to EU approval for ovarian cancer drug

AZ moves closer to EU approval for ovarian cancer drug Meanwhile, Clovis Oncology's rucaparib (formerly developed by Pfizer), AbbVie's veliparib and BioMarin's BMN 673 are in early- to mid-stage testing.

Richard Ranieri leaves Dendreon for Biomarin

Richard Ranieri leaves Dendreon for Biomarin He brings a wealth of human resources experience to the company as we continue our rapid growth,” said Jean-Jacques Bienaime, CEO of BioMarin. ... He has the depth and breadth of global experience that BioMarin needs as it scales its operations to meet

AZ's olaparib enters phase III for ovarian cancer

AZ's olaparib enters phase III for ovarian cancer Tesaro recently started a phase III programme for its niraparib (formerly developed by Merck &Co) in ovarian cancer, while other PARP inhibitors in trials include BioMarin's BMN-673 and Clovis

V Bryan Lawlis joins board of KaloBios

V Bryan Lawlis joins board of KaloBios Dr Lawlis is current president and CEO of Itero Biopharmaceuticals and is a director at several other life sciences companies including Biomarin Pharmaceutical, Geron, and Sutro Biopharmaceuticals.

[ Previous 5 results ] 10 11 12 13 14 15 16 17 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics